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Introduction
The constant development and refinement of non-invasive cardiac imaging over the past two decades have contributed to change our pathophysiological understanding of many conditions and, clinically, have provided new tools for the identification of pre-clinical disease as well as a better understanding on how disease evolves and reaches its terminal stage. The focus of this brief review is to summarise how positron emission tomography (PET), cardiovascular magnetic resonance (CMR) and multi-slice computed tomography (MSCT) have contributed to this process and how their combination (fusion) could further revolutionize cardiology. Obviously, other well established techniques such as echocardiography and single photon emission computed tomography (SPECT) will continue to play an essential role in clinical practice for patient diagnosis and stratification whereas these more expensive and less available techniques will provide clinicians with new tools for the exploration of very early and very late phases of cardiac diseases. Accordingly, this article is divided into 2 parts, one dealing with application of these imaging modalities to pre-clinical disease and one concerning the use of these techniques in patients with overt cardiovascular disease.
Preclinical coronary artery disease and microvascular dysfunction
PET Applying mathematical modeling to tracer kinetics derived from time-activity data, PET allows non-invasive quantification of regional myocardial blood flow (MBF). Oxygen-15 labeled water and nitrogen-13 labeled ammonia have been validated in animals against radioactive microspheres and provide comparable results [1, 2] . The generator-produced cation rubidium-82 has also been used although it provides inferior data due to its reduced extraction fraction at higher flows and its very high positron track which degrades scanner's resolution [3] . Measurement of absolute MBF (i.e. ml/min/g) and coronary flow reserve (CFR) provides information on both the macro-(i.e. epicardial coronary arteries) and the microcirculation (vessels <3-400 µm diameter). In the absence of detectable coronary stenoses, abnormal CFR is a marker of early alterations of vascular reactivity [4, 5] . Coronary endothelial and microcirculatory dysfunction have been demonstrated in patients with coronary risk factors such as hypercholesterolemia, essential hypertension, diabetes mellitus and smoking using a variety of endothelial independent or endothelial dependent stimuli [6] [7] [8] . In other words, assessment of absolute MBF and CFR provides a way to document how risk factors translate into measurable damage to the coronary circulation. A most attractive application appears to be the monitoring of risk factor modification using PET perfusion measurement as a surrogate end-point [9, 10] .
So far only a limited number of studies have assessed the prognostic value of abnormal MBF and CFR. Impaired vasodilator capacity has been demonstrated to have significant prognostic value in patients with both dilated [11, 12] and hypertrophic cardiomyopathy [13] .
Computed tomography The value of CT in the detection of subclinical atherosclerosis is based on assessment of coronary artery calcium (CAC). Both electron beam tomography (EBT) and MSCT can be used to assess CAC. MSCT also allows noninvasive coronary angiography, which is probably more important in advanced coronary artery disease (CAD, see below) [14, 15] . The frequency and extent of CAC increase with age [16] and are higher in men than women [14] . Still, the presence of calcifications in an epicardial coronary artery should not be considered normal and reflects early atherosclerosis. The extent of CAC is a marker which is highly correlated with atherosclerotic disease burden [14, 17] , but is not indicative for obstructive CAD [14, 15, 17] . The so-called Agatson score has been developed to quantify the presence and extent of CAC; for those patients with high risk scores, significant CAD is frequently present. Specifically, for patients with moderate to high risk CAC scores (i.e. scores >100 and >400), the prevalence of obstructive CAD increases significantly [17] [18] [19] . Conversely, a negative or low risk study has a high negative predictive value (≈95%) and virtually excludes significant CAD [18, 19] . Besides diagnosis, CAC is useful for prognostic purposes. There are several large studies (with >1000 patients) in selected high risk but asymptomatic populations who were evaluated for their risk of cardiovascular disease [16, [20] [21] [22] [23] [24] . Figure 1 provides a synopsis of available evidence as to the expected 10-year rate of mortality or myocardial infarction based upon several large published series from Greenland [22] and Shaw [16] as well as a recent meta-analysis [24] . This figure reveals that the relative risk of death or CAD events increases linearly with the extent of CAC. High risk CAC scores >400 are associated with a 10.0-to 12.3-fold higher risk of death or CAD events. More recent data were derived from the St. Francis Heart Study [25] . This concerned a prospective, population-based study with 4903 asymptomatic individuals aged 50-70 years who underwent EBCT to assess CAC. Follow-up was obtained in 4613 (94%) individuals at 4.3 years and 119 had an event related to atherosclerotic cardiovascular disease. Individuals with events had a significantly higher CAC score than individuals without events. Moreover, the relative risk for an event in the presence of a CAC score ≥ 100 was 9.6. Most important, CAC score predicted events independently of standard risk factors and was superior to the Framingham risk score. However, when patients with an elevated CAC score were treated with statins and vitamin C/E, CAC score was not reduced over time, indicating that although CAC score can identify patients at increased risk, the therapeutic implications of an elevated CAC score are not yet established [26] . CMR The strength of CMR in detection of subclinical atherosclerosis is in the field of plaque imaging, at present predominantly applied to large vessels. Initial studies in animal models demonstrated the feasibility of evaluating aortic atherosclerotic plaques. Skinner et al [27] illustrated the use of CMR for atherosclerotic lesions in the abdominal aorta of rabbits. In serial CMR studies, the authors demonstrated the feasibility of evaluating progression of disease. Moreover, some plaque components (e.g. the fibrous cap, necrotic core) could be identified and correlated well with histology and gross examination. Toussaint and colleagues [28] subsequently applied CMR plaque imaging in 6 patients who required surgical carotid endarterectomy. Comparison of the MR images with histology confirmed the feasibility of discrimination of fibrous caps, lipid cores and calcifications in human atheromatous lesions. Following these observational and comparative studies, Corti et al [29] used CMR plaque imaging to assess the response to therapy. In 18 asymptomatic, hypercholesterolemic patients with documented aortic and/or carotid plaques, serial CMR studies demonstrated a significant reduction in atherosclerotic burden (as expressed in vessel wall thickness and vessel area) after 12 months of statin therapy. The next step, currently being evaluated, is the use of intravascular coils with CMR. This approach resulted in substantial improvement in resolution for vessel wall imaging and allows more subtle evaluation of plaque components including lipid, collagen, calcium and thrombus formation. Ex-vivo imaging of the aorta showed a sensitivity and specificity of 83% and 100% respectively for detection of fibrous cap and necrotic core [30] . Substantial data in humans using intravascular MRI are not yet available.
Imaging vulnerable plaques
Atherosclerotic lesions develop in the course of a specific inflammatory process triggered by an initial injury of the endothelium and may result in mechanical destabilization and rupture of the atherosclerotic plaque, potentially leading to thrombosis and vessel occlusion with life-threatening clinical sequelae [31, 32] . Despite primary and secondary prevention, such events still account for one third of all deaths worldwide and constitute a major source of disability and health care costs. Therefore, identifying individual patients with a high risk of plaque rupture is an important challenge in clinical medicine. Several non-invasive techniques including CMR and MSCT are currently being tested for their applicability to identify such patients by assessing morphologic criteria associated with high risk of atherosclerotic plaque rupture. In contrast, non-invasive scintigraphic techniques such as PET make use of radiolabeled molecules (radioligands) designed to specifically target individual inflammatory activities involved in the development of atherosclerotic plaques [33] . Plaque rupture is usually a consequence of inflammatory cell activity within the plaque. Techniques which illustrate plaque anatomy and composition do not provide information on plaque inflammation. F18-fluorodeoxyglucose (FDG) with PET has been used to image inflammatory cell activity. In a study in patients with symptomatic carotid atherosclerosis, FDG with PET (co-registered with CT) has been used to identify inflammation within plaques [34] . The estimated net FDG accumulation rate in symptomatic lesions was 27% higher than in contralateral asymptomatic lesions whilst there was no measurable FDG uptake into normal carotid arteries. A variety of cellular molecular targets involved in the progression and potential rupture of vulnerable plaques have been identified, among these are macrophage density, apoptosis, protease activity and many others [33] . Different PET-based approaches to image these targets are currently under development and could help identifying patients with a future high risk of plaque rupture, especially in combination with high-resolution morphological imaging of the coronary arteries using PET-CT.
Overt cardiovascular disease
Overt disease includes the entire spectrum from diagnosis and prognosis in CAD to evaluation of ischemic cardiomyopathy. As pointed out before, echocardiography and SPECT remain the most important techniques for diagnostic and prognostic purposes. CMR can also be used for diagnosis of CAD; both dobutamine CMR (assessing ischemia looking at inducible wall motion abnormalities) and stress-rest perfusion CMR (assessing ischemia looking at inducible perfusion abnormalities) have been reported in the literature for diagnosis of CAD [35] . PET stress-rest perfusion imaging (mainly using rubidium-82 and nitrogen-13 ammonia) has also been used for diagnosis and prognosis in CAD. Based on pooled analysis of 7 studies with 633 patients, the sensitivity and specificity of PET for detection of CAD were 89% and 86% respectively [36] ; the high specificity is (at least partially) related to attenuation correction. A potential advantage of perfusion imaging with CMR or PET is related to the high spatial resolution of these techniques making differentiation between epi-and endocardial perfusion possible. PET imaging is also useful for determining prognosis. Patients with a normal PET perfusion scan have an excellent prognosis, whereas patients with extensive abnormalities had a 76% event-free survival [37] .
CMR and MSCT: Noninvasive angiography
Although cardiac catheterization allows diagnosis of significant CAD with excellent spatial (0.2 mm) and temporal resolution (5 ms), the technique has still several drawbacks including its high cost and invasive nature. Over the last years, CMR and MSCT have rapidly developed for non-invasive imaging of the coronary arteries. In 1993, the first results on non-invasive coronary angiography with MRI were reported by Manning et al [38] , showing sensitivity and specificity of 90% and 92%, respectively. Additional reports varied significantly with sensitivities ranging from 38% to 88% and specificities ranging from 72% to 100% [39] . Of note, on average 25% of segments are of non-diagnostic quality. It is anticipated that results will further improve with 3 Tesla CMR. Regarding MSCT, the initial studies were performed with 4-slice scanners and pooled data of 11 studies yielded a mean sensitivity of 80% with a specificity of 94% [39] . The percentage of non-assessable segments was on average 22%. Introduction of 16-slice scanners has led to increased accuracy: pooled data of 11 studies yielded a mean sensitivity and specificity of 88% and 96% respectively; on average, 4% of segments were of non-diagnostic quality [39] . The consistently high specificities and negative predictive values that have been reported thusfar underline the potential of the technique to exclude CAD. In particular, specificity of MSCT appears significantly higher as compared to MRI [39] . In addition, further improvement in diagnostic performance is anticipated with the 64-slice scanners. Accordingly, MSCT may currently be the preferred technique for noninvasive angiography [39] . Some patient examples of noninvasive angiography with MSCT are presented in Figure 2 . The major drawbacks of the technique are the radiation burden, which is currently in the range of 10 mSv, and the need for low heart rate during MSCT (obtained by administration of beta-blockers, which is not feasible in all patients). Meta-analysis of the available MSCT and MRI angiographic studies revealed a significantly higher specificity for MSCT [39] , however the techniques are constantly under development which limits meta-analysis of data. An important topic of uncertainty is, which patient populations may benefit most from noninvasive angiography. Results from the aforementioned meta-analysis [39] demonstrated that almost 80% of patients had CAD, illustrating the high prevalence of CAD in the available studies. In the clinical setting however, it may be more useful to perform noninvasive angiography in patients with an intermediate likelihood of CAD.
PET and CMR: Assessment of viability and scar tissue
Assessment of glucose utilization with FDG PET has been used extensively to identify dysfunctional, but viable myocardium and predict improvement in LV function after revascularization [40, 41] . Pooled analysis of 20 studies with 598 patients revealed a sensitivity of 93% to predict recovery of function, which was higher than SPECT imaging with thallium-201 or technetium-99m labeled agents or dobutamine stress echocardiography [42] . According to the ACC/AHA/ASNC guidelines, FDG PET is considered a class I indication for assessment of viability in ischemic cardiomyopathy [36] . FDG can be used in combination with a perfusion tracer, making distinction between (repetitive) stunning, hibernation and (non-)transmural scar tissue possible [43] . Alternatively, FDG can be used alone during hyperinsulinemic euglycemic clamping, allowing for absolute quantification of regional myocardial glucose utilization [44] . This approach may have the highest sensitivity to detect viable myocardium. Most studies have focused on prediction of recovery, but this may not be the ideal endpoint. Improvement in heart failure symptoms, prevention of ongoing LV remodeling, and long-term prognosis may be more important clinically. The currently available studies on long-term outcome consistently demonstrated that viability on FDG PET was associated with a high event rate if patients were treated medically, but also delayed revascularization resulted in worse outcome [41] .
Delayed contrast-enhanced imaging with CMR has become very popular to evaluate patients with ischemic cardiomyopathy [43] . The contrast accumulates in infarcted tissue and animal experiments have demonstrated an excellent agreement between contrastenhanced CMR and the histological extent of infarction. In particular, the high spatial resolution of CMR allows precise delineation between transmural and subendocardial scar tissue (Figures 3 and 4) . Kim and colleagues [46] have evaluated 50 patients undergoing revascularization and demonstrated that the transmurality of the infarcted area was inversely related to the likelihood of recovery after post-revascularization. From a clinical perspective, it is important to realize that contrast-enhanced CMR reflects scar tissue, whereas FDG PET can identify the amount of residual viable myocardium in jeopardized segments. It would therefore be of interest to evaluate the integration of information from both modalities for prediction of functional recovery postrevascularization.
Present clinical applications of PET/CT to cardiology and future perspectives
To optimally evaluate the hemodynamic significance of coronary artery lesions (to guide therapy), integration of anatomic information and the hemodynamic consequences (does the lesion result in ischemia) is needed. PET/CT scanners are currently introduced world-wide, making integration of these 2 parameters possible: angiography with the CT portion and stress-rest perfusion measurements with the PET portion of the system. Preliminary results are encouraging. In a recent study, the concept was evaluated using an early PET/CT scanner with a 4-slice, 0.5 sec rotation CT system, using nitrogen-13 ammonia as a flow tracer. In 25 patients with suspected CAD, PET/CT was performed, yielding a sensitivity and specificity of 90% and 98% respectively, to detect hemodynamically significant stenoses (as compared to the combination of stress-rest PET perfusion imaging and invasive coronary angiography) [47] . With the ongoing development of PET/CT systems, integration of 64-slice scanners and PET perfusion with rubidium-82 will reduce data acquisition, enhance resolution and improve diagnostic performance. To further increase patient throughput and meet the high demand rate for patient studies, it will be important to explore integration of SPECT cameras with high end CT systems. As probably 90% of all questions regarding myocardial perfusion can be solved with SPECT perfusion imaging, for which radiopharmaceuticals are widely available, this is an interesting alternative to PET/CT. As all the technologies are just around the corner, the next 5 years should bring clarity whether integrated procedures using CT and nuclear medicine techniques make clinical sense and are economically viable.
Technical aspects and future development
Although PET has the potential to image and measure pathophysiological and molecular processes in vivo, its position in cardiovascular research and patient care has primarily been based on its capacity to image perfusion and glucose metabolism. To achieve its full potential, a number of major challenges have to be addressed.
Quantification Since the late 70s, spatial resolution of PET scanners has steadily improved, and there is still scope for further improvement. With the improved resolution, the impact of patient movement on quantification becomes more critical, at least if the improved resolution is used to its full potential (e.g. voxel-by-voxel analyses). This highlights the need for methods that are able to correct for patient movement, not only within one scan (e.g. between frames within a dynamic emission scan), but also between scans (e.g. between transmission and emission scans). Also related to the improving spatial resolution, is the need to correct for cardiac and respiratory motion. This can be achieved using gating techniques, especially when the scanner is equipped with list mode acquisition hardware and software. Although this is feasible for static scans, its use for dynamic scans has not been investigated, as it compromises statistical quality of the acquired data. Finally, many new scanners, in particular PET/CT scanners, are 3D only scanners. These scanners are more sensitive than 2D scanners (better image quality), but they also suffer from a much higher contribution of scatter. As a result, more sophisticated scatter correction techniques are needed, in particular to deal with activity from outside the field-of-view of the scanner (e.g. hepatic activity). In addition, attenuation correction methods (singles source, CT scan) need to be validated for quantitative purposes.
Molecular imaging PET allows for imaging and quantification of molecular interactions and pathways with picomolar sensitivity. As most radioligands are metabolized in the human body, development of tracer kinetic models also requires that the presence of labeled metabolites is taken into account. For this purpose combination with magnetic resonance spectroscopy could be very useful. A multitude of processes can be studied, e.g. receptor density, enzyme activity, inflammatory processes and gene expression. In particular, a number of positron labelled tracers for imaging cardiac sympathetic and parasympathetic agonists and receptors with PET have been developed and validated. These include the catecholamine analogue C11-hydroxyephedrine, C11-CGP 12177 for the measurement of beta adrenoceptor densities and C11-MQNB for the measurement of muscarinic receptors [48] . Use of these ligands alone or in combination (e.g. C11-hydroxyephedrine and C11-CGP 12177) have allowed the demonstration of abnormal autonomic function in different cardiac diseases including dilated and hypertrophic cardiomyopathy and idiopathic arrhythmogenic diseases such as the Brugada syndrome [49, 50] . Importantly, the prognostic value of beta adrenoceptor downregulation measured soon after acute myocardial infarction has been recently demonstrated using PET with C11-CGP 12177 [51] .
Clinical applicability Research studies are needed to gain new insights in pathophysiology and to assess the efficacy of therapy. For maximal clinical impact, however, it is important to derive simplified protocols that are calibrated against the more complicated research protocols. A potential danger is that simplified methods are introduced before proper validation. Arterial sampling is less suitable for routine clinical studies. Therefore, the use of image derived input functions (IDIF) should be further evaluated. For example, it appears that the ascending aorta is the optimal structure for defining IDIF in case of FDG, while the left atrium and ventricle are equally suitable in case of water studies. In both cases, however, these regions have to be defined by hand with the inherent risk of interobserver variation. Development of automatic procedures (e.g. cluster analysis) should have high priority. To reduce interobserver variability even further, automatic methods for defining myocardial regions of interest (ROI) should also be developed. Automatic definition of ROIs is not only important for clinical studies (less time-consuming), but also for multicenter trials (standardization). PET data often are analysed on an ROI basis, producing results that do not make optimal use of the resolution of the scanner and heterogeneity within those ROIs may be overlooked. There is a need for methods to derive parametric images, i.e. representation of results on a voxel-by-voxel basis. Initial efforts have been reported, but this clearly is an area that needs further research.
Fusion of the imaging modalities is the future: The challenge of co-registration
From a computational perspective, one of the major benefits of adopting a hardware based approach for image fusion is that it permits the acquisition of co-registered anatomical and functional images. Traditionally, this is achieved at a software level through the use of landmark, surface, or intensity based co-registration techniques. Landmark based methods typically involve either external fiducial or anatomical landmarks, whereas surface and intensity based techniques explore the intrinsic information content of different image features. Despite significant advances in software based co-registration techniques, issues concerning accuracy and user interaction have limited their routine clinical use on a patient-by-patient basis. The real benefit of fusing different imaging modalities, however, is in the ability of using the anatomical information acquired in situ to improve the scan efficiency and resolve complex physiological motion for enhancing the resolution details of the functional image. In the case of PET/CT for example, it is possible to use the CT images for attenuation correction of the PET emission data, thus eliminating the need for a separate and often lengthy PET transmission scan. In addition to increasing the overall scan efficiency, the method also provides effectively noiseless attenuation correction factors that cannot be achieved using the current approaches. Before the technique becomes clinically useful however, there are several technical hurdles to be overcome. These include spatial mismatches arising from patient motion (particularly respiratory induced visceral deformation), errors in the attenuation map due to the use of contrast agents or the presence of metal objects in the patient during the CT scan, truncation of the CT field-of-view, and beam-hardening artefacts [52.53] . Among these, the most challenging issue is the effective handling of respiratory motion because of its poor inter-cycle consistency. For PET/CT, this effect is further amplified due to the fact that CT is normally acquired with breath-hold on full inspiration whereas the PET is acquired during free-breathing. Although cardiac motion due to respiration acts predominantly in the cranio-caudal direction, supplementary translational motion in the other 2 directions is also significant. Furthermore, there is also a degree of rotation of the heart that varies amongst individuals. The degree of non-rigid deformation is found to vary amongst individuals and when present, is most significant in the left ventricular apex, the right atrium and in the region of the right coronary artery. Due to the nature of this complex, non-rigid deformation, effective motion modeling is required to predict the extent of respiratory induced motion in a subject specific manner [54] . This is expected to be an area of active development in future years, as in the case of PET/CT, the benefits of low statistical noise and rapid transmission imaging far outweigh the potential problems listed above.
Concluding remarks
PET has established a role in clinical evaluation of perfusion and metabolism in patients with coronary artery disease. It will continue to have a role in research particularly in molecular imaging. MRI and MSCT are emerging as technologies where clinical application is also being established. Pre-clinical definition of disease is becoming an important focus as early intervention therapies attempt to prevent the progression to established disease. All these advanced modalities provide unique and complementary information on pathophysiology and anatomy. Optimal use will require consideration of this complementary nature, facilitated by fusion and/or hybrid techniques. Continued research to optimize these technologies and to define their clinical role remains a priority for improving the diagnosis, and therapeutic evaluation of patients with cardiovascular disease. Figures   Figure 1. Relative risk of all-cause death, cardiovascular death or myocardial infarction, or overall cardiac events from 2 large observational cohorts (16, 22) and a meta-analysis (24) . 
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